The management of infections caused by Gram-negative bacteria resistant to carbapenems remains a major challenge, even with new therapeutic options.

The attached article, in addition to addressing the “old and new” options against these pathogens, makes important considerations about the role of stewardship in these antimicrobials and rapid diagnoses, directing the rational use of these agents.